Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 76 Researches
7.4
USERS' SCORE
Good
Based on 22 Reviews
8.4
Supplement Facts
Serving Size: 1 Veg Capsule
Amount Per Serving
%DV
Blend of 10 Strains of Probiotic Bacteria: Lactobacillus acidophilus (La-14), Bifidobacterium lactis (Bl-04),Lactobacillus plantarum (Lp-115), Lactobacillus casei (Lc-11),Lactobacillus rhamnosus (Lr-32), Lactobacillus paracasei (Lpc-37),Bifidobacterium breve (Bb-03), Streptococcus thermophilus (St-21),Lactobacillus salivarius (Ls-33), Bifidobacterium longum (BI-05)
100 Billion CFU
*
Top Medical Research Studies
A randomized, double-blind, placebo-controlled trial exploring CECT 7347 (ES1) and heat-treated CECT 7347 (HT-ES1) revealed promising results for diarrhea-predominant irritable bowel syndrome (IBS-D).
We found that after 12 weeks, both ES1 and HT-ES1 significantly reduced symptom severity compared to a placebo, as shown by lower IBS-Symptom Severity Scale scores.
Other improvements included better stool consistency and quality of life. This study marks a breakthrough with the first positive findings for a probiotic or postbiotic from this strain specifically for IBS-D patients.
We found that after 12 weeks, both ES1 and HT-ES1 significantly reduced symptom severity compared to a placebo, as shown by lower IBS-Symptom Severity Scale scores.
Other improvements included better stool consistency and quality of life. This study marks a breakthrough with the first positive findings for a probiotic or postbiotic from this strain specifically for IBS-D patients.
Read More
9
We aimed to understand how Lacticaseibacillus rhamnosus IDCC 3201 (RH 3201) affects irritable bowel syndrome with constipation (IBS-C) through a thorough study. In a randomized, double-blind trial, 30 participants took either RH 3201 or a placebo for 8 weeks.
Those taking RH 3201 experienced significant improvements, including fewer bowel discomforts and reduced bloating issues. We also observed an increase in certain beneficial gut bacteria and a link between specific metabolites and symptom relief. Overall, RH 3201 shows promise as an effective treatment for IBS-C.
Those taking RH 3201 experienced significant improvements, including fewer bowel discomforts and reduced bloating issues. We also observed an increase in certain beneficial gut bacteria and a link between specific metabolites and symptom relief. Overall, RH 3201 shows promise as an effective treatment for IBS-C.
Read More
9
Lactobacillus drink benefits IBS-C
We explored the impact of a Lactobacillus-containing cultured milk drink on individuals with constipation-predominant irritable bowel syndrome (IBS-C). Over 30 days, participants consumed this drink daily while we assessed their clinical symptoms and inflammatory markers.
Impressively, 97.4% reported improvement in symptoms, along with noticeable reductions in intestinal transit time and fecal pH. Evidence also showed lowered levels of pro-inflammatory cytokines in IBS-C participants, supporting potential adjunctive benefits of this treatment for IBS-C patients.
Impressively, 97.4% reported improvement in symptoms, along with noticeable reductions in intestinal transit time and fecal pH. Evidence also showed lowered levels of pro-inflammatory cytokines in IBS-C participants, supporting potential adjunctive benefits of this treatment for IBS-C patients.
Read More
Most Useful Reviews
9.5
Improved condition quickly
After developing irritable bowel syndrome from stress in the military, I had severe abdominal pain and diarrhoea. I tried Now Foods lactobacillus, taking two 100 billion tablets daily. Remarkably, my symptoms improved significantly within days. This product has become part of my daily routine.
Read More
9.5
Eliminated yeast infection
I regularly take lactic acid bacteria for irritable bowel syndrome and Candida vaginitis. Since using this product, my yeast infection symptoms have completely disappeared, which is a huge relief.
Read More
4.5
Essential treatment
Essential for irritable bowel syndrome! This is a must-have! The WeCare app highlights 10 billion species, and Now Foods Lactobacillus is well-known for its cost-effectiveness. The product also offers great value. The capsules are not too large and have no odour, making them easy to take.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 76 Researches
7.4
- All Researches
9.5
This randomized, single-blinded trial evaluated the impact of probiotics, specifically Lactobacillus acidophilus and plantarum, on patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
We found that when added to standard IBS treatment, these probiotics significantly improved symptoms over a 12-week period.
Group B, the probiotic group, experienced better results, including fewer days with pain and greater satisfaction with bowel habits. While both groups saw reductions in IBS severity, the probiotics led to complete remission in many patients, which is promising for future treatment guidelines.
We found that when added to standard IBS treatment, these probiotics significantly improved symptoms over a 12-week period.
Group B, the probiotic group, experienced better results, including fewer days with pain and greater satisfaction with bowel habits. While both groups saw reductions in IBS severity, the probiotics led to complete remission in many patients, which is promising for future treatment guidelines.
Read More
9.5
This randomized, single-blinded trial evaluated the impact of probiotics, specifically Lactobacillus acidophilus and plantarum, on patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
We found that when added to standard IBS treatment, these probiotics significantly improved symptoms over a 12-week period.
Group B, the probiotic group, experienced better results, including fewer days with pain and greater satisfaction with bowel habits. While both groups saw reductions in IBS severity, the probiotics led to complete remission in many patients, which is promising for future treatment guidelines.
We found that when added to standard IBS treatment, these probiotics significantly improved symptoms over a 12-week period.
Group B, the probiotic group, experienced better results, including fewer days with pain and greater satisfaction with bowel habits. While both groups saw reductions in IBS severity, the probiotics led to complete remission in many patients, which is promising for future treatment guidelines.
Read More
A randomized, double-blind, placebo-controlled trial exploring CECT 7347 (ES1) and heat-treated CECT 7347 (HT-ES1) revealed promising results for diarrhea-predominant irritable bowel syndrome (IBS-D).
We found that after 12 weeks, both ES1 and HT-ES1 significantly reduced symptom severity compared to a placebo, as shown by lower IBS-Symptom Severity Scale scores.
Other improvements included better stool consistency and quality of life. This study marks a breakthrough with the first positive findings for a probiotic or postbiotic from this strain specifically for IBS-D patients.
We found that after 12 weeks, both ES1 and HT-ES1 significantly reduced symptom severity compared to a placebo, as shown by lower IBS-Symptom Severity Scale scores.
Other improvements included better stool consistency and quality of life. This study marks a breakthrough with the first positive findings for a probiotic or postbiotic from this strain specifically for IBS-D patients.
Read More
9
Lactobacillus drink benefits IBS-C
We explored the impact of a Lactobacillus-containing cultured milk drink on individuals with constipation-predominant irritable bowel syndrome (IBS-C). Over 30 days, participants consumed this drink daily while we assessed their clinical symptoms and inflammatory markers.
Impressively, 97.4% reported improvement in symptoms, along with noticeable reductions in intestinal transit time and fecal pH. Evidence also showed lowered levels of pro-inflammatory cytokines in IBS-C participants, supporting potential adjunctive benefits of this treatment for IBS-C patients.
Impressively, 97.4% reported improvement in symptoms, along with noticeable reductions in intestinal transit time and fecal pH. Evidence also showed lowered levels of pro-inflammatory cytokines in IBS-C participants, supporting potential adjunctive benefits of this treatment for IBS-C patients.
Read More
9
This study looked into the effects of two probiotic strains, DDS-1 and UABla-12, on alleviating abdominal pain and other IBS symptoms.
We observed that participants taking these probiotics experienced notable reductions in pain severity and overall symptom scores compared to those receiving a placebo.
Specifically, both probiotic groups reported improved bowel habits and stool consistency, enhancing quality of life for adults facing IBS.
Overall, the results suggest that these probiotic strains can be beneficial for managing symptoms of irritable bowel syndrome.
We observed that participants taking these probiotics experienced notable reductions in pain severity and overall symptom scores compared to those receiving a placebo.
Specifically, both probiotic groups reported improved bowel habits and stool consistency, enhancing quality of life for adults facing IBS.
Overall, the results suggest that these probiotic strains can be beneficial for managing symptoms of irritable bowel syndrome.
Read More
User Reviews
USERS' SCORE
Good
Based on 22 Reviews
8.4
- All Reviews
- Positive Reviews
- Negative Reviews
9.5
Improved condition quickly
After developing irritable bowel syndrome from stress in the military, I had severe abdominal pain and diarrhoea. I tried Now Foods lactobacillus, taking two 100 billion tablets daily. Remarkably, my symptoms improved significantly within days. This product has become part of my daily routine.
Read More
9.5
Eliminated yeast infection
I regularly take lactic acid bacteria for irritable bowel syndrome and Candida vaginitis. Since using this product, my yeast infection symptoms have completely disappeared, which is a huge relief.
Read More
4.5
Essential treatment
Essential for irritable bowel syndrome! This is a must-have! The WeCare app highlights 10 billion species, and Now Foods Lactobacillus is well-known for its cost-effectiveness. The product also offers great value. The capsules are not too large and have no odour, making them easy to take.
Read More
3.8
Effective relief
I've tried other brands, but this one works excellently. My irritable bowel syndrome caused me to have diarrhoea, but it's now under control.
Read More
9.5
Excellent for IBS
This product is excellent for managing irritable bowel syndrome.
Read More
Frequently Asked Questions
No FAQs are available for this product and symptom.
References
- Sarkawi M, Raja Ali RA, Abdul Wahab N, Abdul Rathi ND, Mokhtar NM. A randomized, double-blinded, placebo-controlled clinical trial on Lactobacillus-containing cultured milk drink as adjuvant therapy for depression in irritable bowel syndrome. Sci Rep. 2024;14:9478. doi:10.1038/s41598-024-60029-2
- Shanshal SA, Alsaaty MH, Al-Qazaz H, Al-Zidan RN. Two Lactobacilli strains as adjuvant therapy in the management of irritable bowel syndrome: a randomized control trial. Ceska Slov Farm. 2024;72:233.
- Shanshal SA, Alsaaty MH, Al-Qazaz H, Al-Zidan RN. Two Lactobacilli strains as adjuvant therapy in the management of irritable bowel syndrome: a randomized control trial. Ceska Slov Farm. 2024;73:233.
- Chang YH, Choi YJ, Shin CM, Moon JS, Kim TY, et al. Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study. J Neurogastroenterol Motil. 2024;30:73. doi:10.5056/jnm23036
- Drozdov VN, Shikh EV, Astapovskii AA, Khalaidzheva KN, Solovieva SA, et al. [Clinical efficacy of a modern probiotic for the correction of intestinal microflora in patients with irritable bowel syndrome with diarrhea and antibiotic-associated diarrhea]. Vopr Pitan. 2023;92:92. doi:10.33029/0042-8833-2023-92-4-92-103
- Cocetta V, Giacomini I, Tinazzi M, Berretta M, Quagliariello V, et al. Maintenance of intestinal epithelial barrier integrity by a combination of probiotics, herbal extract, and vitamins. Minerva Pediatr (Torino). 2023. doi:10.23736/S2724-5276.23.07128-8
- Shin SY, Park S, Moon JM, Kim K, Kim JW, et al. Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Post Hoc Analysis of a Randomized Clinical Trial. J Neurogastroenterol Motil. 2022;28:642. doi:10.5056/jnm21202
- Mokhtar NM, Jaafar NM, Alfian E, Mohd Rathi ND, Abdul Rani R, et al. Clinical assessment and cytokines level in constipation-predominant irritable bowel syndrome participants treated with Lactobacillus-containing cultured milk drink. Acta Gastroenterol Belg. 2021;84:585. doi:10.51821/84.4.009
- Skrzydło-Radomańska B, Prozorow-Król B, Cichoż-Lach H, Majsiak E, Bierła JB, et al. The Effectiveness of Synbiotic Preparation Containing and Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant Irritable Bowel Syndrome-A Randomized Double-Blind, Placebo-Controlled Study. Nutrients. 2020;12. doi:10.3390/nu12071999
- Martoni CJ, Srivastava S, Leyer GJ. DDS-1 and UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial. Nutrients. 2020;12. doi:10.3390/nu12020363
- Sadrin S, Sennoune S, Gout B, Marque S, Moreau J, et al. A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial. Dig Liver Dis. 2020;52:534. doi:10.1016/j.dld.2019.12.009
- Preston K, Krumian R, Hattner J, de Montigny D, Stewart M, et al. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study. Benef Microbes. 2018;9:697. doi:10.3920/BM2017.0105
- Leventogiannis K, Gkolfakis P, Spithakis G, Tsatali A, Pistiki A, et al. Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth. Probiotics Antimicrob Proteins. 2019;11:627. doi:10.1007/s12602-018-9401-3
- Bogovič Matijašić B, Obermajer T, Lipoglavšek L, Sernel T, Locatelli I, et al. Effects of synbiotic fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis ssp. lactis BB-12 on the fecal microbiota of adults with irritable bowel syndrome: A randomized double-blind, placebo-controlled trial. J Dairy Sci. 2016;99:5008. doi:10.3168/jds.2015-10743
- Yoon H, Park YS, Lee DH, Seo JG, Shin CM, et al. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Biochem Nutr. 2015;57:129. doi:10.3164/jcbn.15-14
- Yoon JS, Sohn W, Lee OY, Lee SP, Lee KN, et al. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol. 2014;29:52. doi:10.1111/jgh.12322
- Barbaro MR, Bianco F, Cremon C, Marasco G, Stanghellini V, et al. A Probiotic Mixture of LR 32, BL 04, and BB 536 Counteracts the Increase in Permeability Induced by the Mucosal Mediators of Irritable Bowel Syndrome by Acting on Zonula Occludens 1. Int J Mol Sci. 2025;26. doi:10.3390/ijms26062656
- Gąsiorowska A, Romanowski M, Walecka-Kapica E, Kaczka A, Chojnacki C, et al. Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome-A Randomized, Double-Blind, Placebo-Controlled Study. J Clin Med. 2024;14. doi:10.3390/jcm14010006
- Kwon H, Nam EH, Kim H, Jo H, Bang WY, et al. Effect of Lacticaseibacillus rhamnosus IDCC 3201 on irritable bowel syndrome with constipation: a randomized, double-blind, and placebo-controlled trial. Sci Rep. 2024;14:22384. doi:10.1038/s41598-024-72887-x
- Zhang L, Ni X, Jiang M, Du M, Zhang S, et al. Strains for Alleviation of Irritable Bowel Disease and Chronic Fatigue Syndrome. Microorganisms. 2024;12. doi:10.3390/microorganisms12061081
- Drozdov VN, Shikh EV, Astapovskii AA, Khalaidzheva KN, Solovieva SA, et al. [Clinical efficacy of a modern probiotic for the correction of intestinal microflora in patients with irritable bowel syndrome with diarrhea and antibiotic-associated diarrhea]. Vopr Pitan. 2023;92:92. doi:10.33029/0042-8833-2023-92-4-92-103
- Skrzydło-Radomańska B, Prozorow-Król B, Cichoż-Lach H, Majsiak E, Bierła JB, et al. The Effectiveness of Synbiotic Preparation Containing and Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant Irritable Bowel Syndrome-A Randomized Double-Blind, Placebo-Controlled Study. Nutrients. 2020;12. doi:10.3390/nu12071999
- Bonfrate L, Di Palo DM, Celano G, Albert A, Vitellio P, et al. Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients. Eur J Clin Invest. 2020;50:e13201. doi:10.1111/eci.13201
- Ding FCL, Karkhaneh M, Zorzela L, Jou H, Vohra S. Probiotics for paediatric functional abdominal pain disorders: A rapid review. Paediatr Child Health. 2019;24:383. doi:10.1093/pch/pxz036
- Nocerino R, Di Costanzo M, Bedogni G, Cosenza L, Maddalena Y, et al. Dietary Treatment with Extensively Hydrolyzed Casein Formula Containing the Probiotic Lactobacillus rhamnosus GG Prevents the Occurrence of Functional Gastrointestinal Disorders in Children with Cow's Milk Allergy. J Pediatr. 2019;213:137. doi:10.1016/j.jpeds.2019.06.004
- Hojsak I. Probiotics in Functional Gastrointestinal Disorders. Adv Exp Med Biol. 2019;1125:121. doi:10.1007/5584_2018_321
- Han X, Lee A, Huang S, Gao J, Spence JR, et al. Lactobacillus rhamnosus GG prevents epithelial barrier dysfunction induced by interferon-gamma and fecal supernatants from irritable bowel syndrome patients in human intestinal enteroids and colonoids. Gut Microbes. 2019;10:59. doi:10.1080/19490976.2018.1479625
- Preston K, Krumian R, Hattner J, de Montigny D, Stewart M, et al. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study. Benef Microbes. 2018;9:697. doi:10.3920/BM2017.0105
- Wegh CAM, Benninga MA, Tabbers MM. Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic Review. J Clin Gastroenterol. 2018;52 Suppl 1, Proceedings from the 9th Probiotics, Prebiotics and New Foods, Nutraceuticals and Botanicals for Nutrition & Human and Microbiota Health Meeting, held in Rome, Italy from September 10 to 12, 2017:S10. doi:10.1097/MCG.0000000000001054
- Darbaky Y, Evrard B, Patrier S, Falenta J, Garcin S, et al. Oral probiotic treatment of Lactobacillus rhamnosus Lcr35 prevents visceral hypersensitivity to a colonic inflammation and an acute psychological stress. J Appl Microbiol. 2017;122:188. doi:10.1111/jam.13320
- Yoon H, Park YS, Lee DH, Seo JG, Shin CM, et al. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Biochem Nutr. 2015;57:129. doi:10.3164/jcbn.15-14
- Cruchet S, Furnes R, Maruy A, Hebel E, Palacios J, et al. The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts. Paediatr Drugs. 2015;17:199. doi:10.1007/s40272-015-0124-6
- Chung HG, Min YW, Lee C, Hong SN, Won JY, et al. Effects of Novel Probiotics in a Murine Model of Irritable Bowel Syndrome. Korean J Gastroenterol. 2020;75:141. doi:10.4166/kjg.2020.75.3.141
- Gąsiorowska A, Romanowski M, Walecka-Kapica E, Kaczka A, Chojnacki C, et al. Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome-A Randomized, Double-Blind, Placebo-Controlled Study. J Clin Med. 2024;14. doi:10.3390/jcm14010006
- Martin FP, Cominetti O, Berger B, Combremont S, Marquis J, et al. Metabolome-associated psychological comorbidities improvement in irritable bowel syndrome patients receiving a probiotic. Gut Microbes. 2024;16:2347715. doi:10.1080/19490976.2024.2347715
- Srivastava S, Basak U, Naghibi M, Vijayakumar V, Parihar R, et al. A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live CECT 7347 (ES1) and heat-treated CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome. Gut Microbes. 2024;16:2338322. doi:10.1080/19490976.2024.2338322
- Chang YH, Choi YJ, Shin CM, Moon JS, Kim TY, et al. Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study. J Neurogastroenterol Motil. 2024;30:73. doi:10.5056/jnm23036
- Drozdov VN, Shikh EV, Astapovskii AA, Khalaidzheva KN, Solovieva SA, et al. [Clinical efficacy of a modern probiotic for the correction of intestinal microflora in patients with irritable bowel syndrome with diarrhea and antibiotic-associated diarrhea]. Vopr Pitan. 2023;92:92. doi:10.33029/0042-8833-2023-92-4-92-103
- Lenoir M, Wienke J, Fardao-Beyler F, Roese N. An 8-Week Course of Bifidobacterium longum 35624 Is Associated with a Reduction in the Symptoms of Irritable Bowel Syndrome. Probiotics Antimicrob Proteins. 2025;17:315. doi:10.1007/s12602-023-10151-w
- Khoo XH, Chong CW, Talha AM, Philip K, Teh CS, et al. The impact of diet and ethnicity on gut microbiota variation in irritable bowel syndrome: A multi-center study. J Gastroenterol Hepatol. 2023;38:1259. doi:10.1111/jgh.16174
- Nakamura Y, Suzuki S, Murakami S, Nishimoto Y, Higashi K, et al. Integrated gut microbiome and metabolome analyses identified fecal biomarkers for bowel movement regulation by BB536 supplementation: A RCT. Comput Struct Biotechnol J. 2022;20:5847. doi:10.1016/j.csbj.2022.10.026
- Yakovenko EP, Strokova TV, Ivanov AN, Iakovenko AV, Gioeva IZ, et al. [The effectiveness of a probiotic containing Bifidobacterium longum BB-46 and Enterococcus faecium ENCfa-68 in the treatment of post-infectious irritable bowel syndrome. Prospective randomized comparative study]. Ter Arkh. 2022;94:180. doi:10.26442/00403660.2022.02.201368
- Groeger D, Murphy EF, Tan HTT, Larsen IS, O'Neill I, et al. Interactions between symptoms and psychological status in irritable bowel syndrome: An exploratory study of the impact of a probiotic combination. Neurogastroenterol Motil. 2023;35:e14477. doi:10.1111/nmo.14477
- Sabaté JM, Iglicki F. Effect of 35624 on disease severity and quality of life in patients with irritable bowel syndrome. World J Gastroenterol. 2022;28:732. doi:10.3748/wjg.v28.i7.732
- Di Pierro F, Pane M. Bifidobacterium longum W11: Uniqueness and individual or combined clinical use in association with rifaximin. Clin Nutr ESPEN. 2021;42:15. doi:10.1016/j.clnesp.2020.12.025
- Caviglia GP, Tucci A, Pellicano R, Fagoonee S, Rosso C, et al. Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with ES1 for 8 or 12 Weeks: A Preliminary Report. J Clin Med. 2020;9. doi:10.3390/jcm9082353
- Skrzydło-Radomańska B, Prozorow-Król B, Cichoż-Lach H, Majsiak E, Bierła JB, et al. The Effectiveness of Synbiotic Preparation Containing and Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant Irritable Bowel Syndrome-A Randomized Double-Blind, Placebo-Controlled Study. Nutrients. 2020;12. doi:10.3390/nu12071999
- Bonfrate L, Di Palo DM, Celano G, Albert A, Vitellio P, et al. Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients. Eur J Clin Invest. 2020;50:e13201. doi:10.1111/eci.13201
- Buhner S, Hahne H, Hartwig K, Li Q, Vignali S, et al. Protease signaling through protease activated receptor 1 mediate nerve activation by mucosal supernatants from irritable bowel syndrome but not from ulcerative colitis patients. PLoS One. 2018;13:e0193943. doi:10.1371/journal.pone.0193943
- Gąsiorowska A, Romanowski M, Walecka-Kapica E, Kaczka A, Chojnacki C, et al. Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome-A Randomized, Double-Blind, Placebo-Controlled Study. J Clin Med. 2024;14. doi:10.3390/jcm14010006
- JanssenDuijghuijsen L, van den Belt M, Rijnaarts I, Vos P, Guillemet D, et al. Acacia fiber or probiotic supplements to relieve gastrointestinal complaints in patients with constipation-predominant IBS: a 4-week randomized double-blinded placebo-controlled intervention trial. Eur J Nutr. 2024;63:1983. doi:10.1007/s00394-024-03398-8
- Drozdov VN, Shikh EV, Astapovskii AA, Khalaidzheva KN, Solovieva SA, et al. [Clinical efficacy of a modern probiotic for the correction of intestinal microflora in patients with irritable bowel syndrome with diarrhea and antibiotic-associated diarrhea]. Vopr Pitan. 2023;92:92. doi:10.33029/0042-8833-2023-92-4-92-103
- Skrzydło-Radomańska B, Prozorow-Król B, Kurzeja-Mirosław A, Cichoż-Lach H, Laskowska K, et al. The Efficacy and Safety of Single-Strain Probiotic Formulations Containing or in Adult Patients with Irritable Bowel Syndrome-A Randomized Double-Blind Placebo-Controlled Three-Arm Interventional Trial. J Clin Med. 2023;12. doi:10.3390/jcm12144838
- Boonma P, Shapiro JM, Hollister EB, Badu S, Wu Q, et al. Probiotic VSL#3 Treatment Reduces Colonic Permeability and Abdominal Pain Symptoms in Patients With Irritable Bowel Syndrome. Front Pain Res (Lausanne). 2021;2:691689. doi:10.3389/fpain.2021.691689
- Xu H, Ma C, Zhao F, Chen P, Liu Y, et al. Adjunctive treatment with probiotics partially alleviates symptoms and reduces inflammation in patients with irritable bowel syndrome. Eur J Nutr. 2021;60:2553. doi:10.1007/s00394-020-02437-4
- Skrzydło-Radomańska B, Prozorow-Król B, Cichoż-Lach H, Majsiak E, Bierła JB, et al. The Effectiveness of Synbiotic Preparation Containing and Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant Irritable Bowel Syndrome-A Randomized Double-Blind, Placebo-Controlled Study. Nutrients. 2020;12. doi:10.3390/nu12071999
- Szajewska H, Hojsak I. Health benefits of GG and subspecies BB-12 in children. Postgrad Med. 2020;132:441. doi:10.1080/00325481.2020.1731214
- Martoni CJ, Srivastava S, Leyer GJ. DDS-1 and UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial. Nutrients. 2020;12. doi:10.3390/nu12020363
- Le Nevé B, Derrien M, Tap J, Brazeilles R, Cools Portier S, et al. Fasting breath H2 and gut microbiota metabolic potential are associated with the response to a fermented milk product in irritable bowel syndrome. PLoS One. 2019;14:e0214273. doi:10.1371/journal.pone.0214273
- Leventogiannis K, Gkolfakis P, Spithakis G, Tsatali A, Pistiki A, et al. Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth. Probiotics Antimicrob Proteins. 2019;11:627. doi:10.1007/s12602-018-9401-3
- Baştürk A, Artan R, Yılmaz A. Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: A randomized controlled trial. Turk J Gastroenterol. 2016;27:439. doi:10.5152/tjg.2016.16301
- Yoon H, Park YS, Lee DH, Seo JG, Shin CM, et al. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Biochem Nutr. 2015;57:129. doi:10.3164/jcbn.15-14
- Eskesen D, Jespersen L, Michelsen B, Whorwell PJ, Müller-Lissner S, et al. Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial. Br J Nutr. 2015;114:1638. doi:10.1017/S0007114515003347
- Veiga P, Pons N, Agrawal A, Oozeer R, Guyonnet D, et al. Changes of the human gut microbiome induced by a fermented milk product. Sci Rep. 2014;4:6328. doi:10.1038/srep06328
- Yoon JS, Sohn W, Lee OY, Lee SP, Lee KN, et al. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol. 2014;29:52. doi:10.1111/jgh.12322
- Drozdov VN, Shikh EV, Astapovskii AA, Khalaidzheva KN, Solovieva SA, et al. [Clinical efficacy of a modern probiotic for the correction of intestinal microflora in patients with irritable bowel syndrome with diarrhea and antibiotic-associated diarrhea]. Vopr Pitan. 2023;92:92. doi:10.33029/0042-8833-2023-92-4-92-103
- Shin SY, Park S, Moon JM, Kim K, Kim JW, et al. Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Post Hoc Analysis of a Randomized Clinical Trial. J Neurogastroenterol Motil. 2022;28:642. doi:10.5056/jnm21202
- Yoon JY, Cha JM, Oh JK, Tan PL, Kim SH, et al. Probiotics Ameliorate Stool Consistency in Patients with Chronic Constipation: A Randomized, Double-Blind, Placebo-Controlled Study. Dig Dis Sci. 2018;63:2754. doi:10.1007/s10620-018-5139-8
- Yoon H, Park YS, Lee DH, Seo JG, Shin CM, et al. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Biochem Nutr. 2015;57:129. doi:10.3164/jcbn.15-14
- Yoon JS, Sohn W, Lee OY, Lee SP, Lee KN, et al. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol. 2014;29:52. doi:10.1111/jgh.12322
- Ortiz-Lucas M, Tobías A, Saz P, Sebastián JJ. Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis. Rev Esp Enferm Dig. 2013;105:19.
- Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, et al. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Gastroenterol. 2012;46:220. doi:10.1097/MCG.0b013e31823712b1
- Zeng J, Li YQ, Zuo XL, Zhen YB, Yang J, et al. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2008;28:994. doi:10.1111/j.1365-2036.2008.03818.x
- Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, et al. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol Clin Biol. 2008;32:147. doi:10.1016/j.gcb.2007.06.001
- Astegiano M, Pellicano R, Terzi E, Simondi D, Rizzetto M. Treatment of irritable bowel syndrome. A case control experience. Minerva Gastroenterol Dietol. 2006;52:359.
- Brigidi P, Vitali B, Swennen E, Bazzocchi G, Matteuzzi D. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol. 2001;152:735.
